

Monza, April 7, 2025

Subject: Support for Inclusion of Blinatumomab in the WHO List of Essential Medicines for Children

Dear WHO Expert Committee,


I am writing to express my strong support for the inclusion of **blinatumomab** on the **WHO Model List of Essential Medicines for Children (EMLc)**.

Blinatumomab has demonstrated significant clinical benefit in the treatment of **acute lymphoblastic leukemia** in children. As a bispecific T-cell engager, it provides a targeted and effective option for patients with poor prognosis, many of whom do not respond to conventional chemotherapy. Its inclusion on the EMLc would be a critical step toward improving access to this innovative therapy in low- and middle-income countries, where treatment options are often limited.

Including blinatumomab in the EMLc would align with the goals of the **WHO Global Initiative for Childhood Cancer (GICC)** and help reduce survival disparities by ensuring that essential, high-impact cancer medicines are made more widely available.

I respectfully urge the Committee to give this application full consideration and to support the global effort to expand access to life-saving treatment for children with cancer.

Sincerely,



Valentino Conter, MD, Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy

(valentino.conter@gmail.com)